Precipio announces shareholder update call to kick off 2020
January 13 2020 - 05:00PM
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),
announced that on Monday, January 20th at 5pm it will conduct a
shareholder update call with regard to several strategic
initiatives for 2020 as well as the current status of IV-cell and
Hemescreen deployment and the diversification of our business model
into the products sector.
The conference call may be accessed by calling
844-695-5519 (international callers dial 1-412-902-6760). All
callers should ask for the Precipio Inc. conference call.
Participants may also pre-register for the conference call at
http://dpregister.com/10138459 and will receive a
calendar invite and a direct dial-in number, bypassing the
operator.
Listeners interested in submitting questions in
advance should email their questions to
investors@precipiodx.com and management will do its best to
address those questions during the call. A replay of the call will
be available approximately 24 hours after the call and may be
accessed via the Investors page on Precipio's website,
http://www.precipiodx.com/investors.html.
About Precipio
Precipio has built a platform designed to
eradicate the problem of misdiagnosis by harnessing the intellect,
expertise and technology developed within academic institutions and
delivering quality diagnostic information to physicians and their
patients worldwide. Through its collaborations with world-class
academic institutions specializing in cancer research, diagnostics
and treatment such as the Yale School of Medicine, Harvard’s
Dana-Farber Cancer Institute and the University of Pennsylvania,
Precipio offers a new standard of diagnostic accuracy enabling the
highest level of patient care. For more information, please visit
www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements,” within the meaning of
federal securities laws, including statements related to ICP
technology, including financial projections related thereto and
potential market opportunity, plans and prospects and other
statements containing the words “anticipate,” “intend,” “may,”
“plan,” “predict,” “will,” “would,” “could,” “should,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The Company’s actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Company’s definitive proxy
statement filed on May 29, 2018, the Company’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2019 and on the
Annual Report on Form 10-K for the year ended December 31, 2018 as
well as the Company’s prior filings and from time to time in the
Company’s subsequent filings with the Securities and Exchange
Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ
materially from those referred to in such statements. All
information in this press release is as of the date of the release
and the Company does not undertake any duty to update this
information, including any forward-looking statements, unless
required by law.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2023 to Mar 2024